Integrated Biopharma Inc (INBP): Total Liabilities
$7.67M
As of 2026-06-30
$7.01M
As of 2026-09-30
+5.3%
3-year compound annual growth
-7.1%
5-year compound annual growth
-10.1%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $7.67M | +67.3% | 2026-09-25, Balance as of period end |
| 2025-06-30 | $4.58M | -34.2% | 2026-09-25, Balance as of period end |
| 2024-06-30 | $6.97M | +6.1% | 2025-09-23, Balance as of period end |
| 2023-06-30 | $6.57M | -1.6% | 2024-09-20, Balance as of period end |
| 2022-06-30 | $6.67M | -39.9% | 2023-09-15, Balance as of period end |
| 2021-06-30 | $11.11M | -34.2% | 2022-09-13, Balance as of period end |
| 2020-06-30 | $16.88M | -5.7% | 2021-09-02, Balance as of period end |
| 2019-06-30 | $17.90M | -9.6% | 2020-09-23, Balance as of period end |
| 2018-06-30 | $19.80M | -6.3% | 2019-08-29, Balance as of period end |
| 2017-06-30 | $21.12M | -5.2% | 2018-09-12, Balance as of period end |
| 2016-06-30 | $22.28M | +6.4% | 2017-09-01, Balance as of period end |
| 2015-06-30 | $20.94M | -3.7% | 2016-09-02, Balance as of period end |
| 2014-06-30 | $21.74M | -5.1% | 2015-09-04, Balance as of period end |
| 2013-06-30 | $22.90M | +2.9% | 2014-09-08, Balance as of period end |
| 2012-06-30 | $22.26M | +4.3% | 2013-09-30, Balance as of period end |
| 2011-06-30 | $21.34M | n/a | 2012-10-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $7.67M | +67.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $112.27M | -16.7% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $18.08M | +2.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
Compare INBP, XLO, CPIX, AQST side by side · Screen every company in Pharmaceutical Preparations ↗